News|Videos|March 12, 2025

RX Review: The role of needle-free epinephrine in pediatric allergy for 2025

Name: RX Review: The role of needle-free epinephrine in pediatric allergy for 2025
Uploaded: 2025-03-12T12:02:00Z
Duration: 7M22S
Description: RX Review: The role of needle-free epinephrine in pediatric allergy for 2025

Author(s)Brian Schroer, MD, Colleen Kraft, MD, MBA, Russell Traister, MD

RX Review: Pediatric Allergy and Anaphylaxis Management in 2025

In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management.

In this Contemporary Pediatrics and HCPLive RX Review discussion, moderator Brian Schroer, MD, speaks with Colleen Kraft, MD, and Russell Traister, MD, about the impact of needle-free epinephrine options, including epinephrine nasal spray (neffy) which received approval for treating type 1 allergic reactions in patients aged 4 years and older weighing at least 30 kg on March 5, 2025.¹